A patient walks in for a filler appointment, gets injected by a nurse she’s never met before, and later asks who actually signed off on her treatment plan. Nobody has a clean answer. That gap, between who’s supposed to be supervising a procedure and who actually is, sits behind a growing share of the malpractice claims hitting aesthetic practices right now.
At GAC 2026, that gap gets a real hearing.
The 2026 Legal Forum, part of the Focus Sessions track on Saturday, November 7, in the Cowrie room, brings together nine attorneys to work through the exact scenarios keeping practice owners up at night.
The Three Biggest Legal Issues Facing Aesthetic Providers
The legal questions facing aesthetic practices aren’t limited to one area of the business. They affect who can provide treatment, how medications are prescribed and how patient expectations are managed before a procedure ever begins.
Is Your Treatment Room Actually Physician-Supervised?
Corporate practice of medicine rules aren’t fading into the background. If anything, enforcement is intensifying. In a recent statewide sweep, New York’s Department of State inspected 223 med spa businesses and cited 87 for practicing medicine without physician ownership or control. That’s nearly 40% of the businesses inspected found to be out of compliance.
In such sweeps, regulators have a specific target in mind: the medical director in name only. State boards now expect a designated physician who maintains a physical presence, documents clinical oversight and actually performs the good faith exams tied to their license, not someone who signed a contract and never sets foot in the building.
But oversight is only one part of the compliance equation. Ownership matters just as much. California and New York continue to enforce corporate practice of medicine doctrines strictly enough that an MSO structure separating business operations from clinical decisions has to leave real autonomy with the licensed practitioner, not just on paper.
Is Your GLP-1 Program Compliant?
Weight management has become one of the fastest-growing services for med spas and practice owners, but it’s also become the fastest-growing source of legal exposure. Prescribing GLP-1s through an online intake form, with no live clinical evaluation and no real aftercare plan, has drawn direct scrutiny from the FTC and state medical boards.
The medications themselves have also become a compliance issue. After declaring the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, the FDA gave compounding pharmacies a matter of months to wind down. By mid-2025, compounding pharmacies could no longer produce copies of Ozempic, Wegovy, Mounjaro and Zepbound. Today, compounded semaglutide or tirzepatide generally requires a documented, patient-specific clinical need that, for whatever reason, the brand-name version cannot meet (which, realistically, rarely happens).
The FDA reinforced that position in September 2025 by issuing more than 50 warning letters to compounding pharmacies and telehealth companies over the marketing and sale of compounded GLP-1 medications. Among the agency’s concerns were claims suggesting compounded products were equivalent to, or interchangeable with, FDA-approved drugs. Practices whose marketing relies on messaging such as “the same active ingredient for less” should review those claims carefully in light of the FDA’s enforcement activity.
Is Your Marketing Creating Legal Problems?
Before-and-after photos, patient testimonials and AI-powered consultation tools can become another source of legal exposure.
Regulators are scrutinizing unsubstantiated results claims, testimonials published without written authorization and photos used without documented patient consent. Disclaimers such as “results may vary” are not optional fine print. They are an expected safeguard, and consent should be secured before any patient image appears on a website, social platform or paid ad.
AI introduces a newer layer of risk. Facial analysis tools and predictive consultation software can shape a patient’s expectations before they ever meet with a provider, raising two important questions: What happens to their image after it is uploaded, and do they understand how much of the potential result they saw was generated by software?
The law is still developing in both areas, but the underlying consent issues are familiar. Patients need to understand how their information will be used, what the technology can and cannot predict, and where software ends and clinical judgment begins. A rushed or vague consent process leaves room for misunderstanding and remains a common source of malpractice exposure across the industry.
Get Real Guidance on Navigating Legal Challenges at GAC 2026
Knowing where the risks are is only the first step. The harder part is understanding how the law applies to your medical director agreement, prescribing process, ownership structure or growth plans.
That’s what the 2026 Legal Forum at GAC is for. It’s a focused session on Saturday, November 7, that puts nine attorneys in the room at once, including Brad Adatto, Kathleen Stillwell, Jennifer Wiggins, Leiza Dolghih, Sam Pondrom, Jonathon Eskow, Greg Rutstein, Benjamin Hernandez and Jeff Segal. Most conferences offer a single attorney presenting a broad overview, but GAC gives attendees access to a full panel of experts.
Legal risk also appears throughout the broader business track. Kathleen Stillwell covers malpractice exposure specific to plastic surgery, dermatology and aesthetic practices. Vahe Tirakyan examines how surgeons can unintentionally create the conditions for a lawsuit. Sam Pondrom looks at the role staff training plays in reducing or increasing exposure, while Jeff Segal opens the track with strategies for de-escalating angry patients before a complaint becomes something larger.
None of these sessions replaces advice from your own attorney. They can, however, help you identify the right questions, recognize gaps in your current approach and hear directly from attorneys who work within this industry.
Bring Your Questions to GAC 2026
The legal landscape for aesthetic practices is changing quickly, but you don’t have to figure it out alone.
Join hundreds of practice owners, physicians and industry leaders at GAC 2026 for practical education on compliance, risk management and the business of aesthetics. Register today and leave with answers you can apply to your practice immediately.
